Newsfile Corp
09 Aug 2026, 10:32 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ADMA Biologics is accused of using channel stuffing to artificially inflate its reported revenue. — Allegations of revenue manipulation through channel stuffing typically lead to significant price drops due to loss of trust in financial reporting.
-0.80ADMA Biologics is alleged to have engaged in undisclosed related party transactions and lacked adequate internal controls. — Poor internal controls and hidden related-party dealings suggest systemic governance failures and potential for further financial irregularities.
-0.60A securities class action lawsuit has been filed against ADMA Biologics for materially false and misleading statements between August 2024 and March 2026. — While common, the existence of a class action introduces legal liability and potential settlement costs that weigh on the company's valuation.
-0.40Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is facing a securities class action lawsuit alleging channel stuffing and misleading statements.
The company is mentioned in the context of a securities class action lawsuit deadline.
The company is mentioned in the context of a securities class action lawsuit deadline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
13h ago
